在斑马鱼幼虫中对迪克洛芬雅克的剂量依赖的神经行为和分子反应
1Department of Basic Sciences, Faculty of Fisheries, Atatürk University, Erzurum, Türkiye.
Journal of applied toxicology : JAT
|February 4, 2026
概括
斑马鱼幼虫暴露在迪克洛芬纳克 (DCF) 中会破坏行为,神经递质代谢和昼夜节律,导致氧化应激. 这些发现揭示了制药污染物在水生生态系统中的多层次风险.
科学领域:
- 环境毒理学环境毒理学
- 水生生态毒理学 水生生态毒理学
- 神经毒理学 神经毒理学
背景情况:
- 药品,如二二 (DCF),由于废水处理不完整而污染水环境.
- DCF是一种广泛使用的非类固醇抗炎药物,已知会在水生生物中引起神经毒性和行为障碍.
研究的目的:
- 研究DCF暴露对斑马鱼幼虫氧化应激,昼夜节律和行为的影响.
- 为了分析对DCF暴露的反应中的分子水平变化.
主要方法:
- 斑马鱼幼虫在120小时内暴露在0.5,2.5和12.5μg/L的DCF中.
- 分析了SOD,CAT,GPX和ACHE酶活动和氧化应激的基因表达.
- 对行为和昼夜节律进行了tighmotaxis和运动运动活动分析.
- 检查了bdnf,5ht4,crhr,bmal1,per和gnat2.2的基因表达.
主要成果:
- 暴露于DCF显著影响了行为活动和神经递质代谢.
- 观察到氧化应激增加和昼夜节律中断的证据.
- 分子分析显示DCF影响与视网膜相关的基因和神经发育途径.
结论:
- 迪克洛芬雅克暴露会诱导斑马鱼幼虫的多层次不良影响,影响行为,神经化学和生理过程.
- 像DCF这样的药物的环境度对水生生态系统中的神经发育构成重大风险.
- 这项研究强调了对药物污染物的复杂生物反应,即使在低剂量下也是如此.
相关概念视频
Dose-Response Relationship: Overview
5.1K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.1K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
689
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
689
Dose-Response Relationship: Potency and Efficacy
6.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.6K
Dose-Response Relationship: Selectivity and Specificity
9.8K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.8K
Dose Size and Dosing Frequency: Determination Methods
307
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
307
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
246
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
246


